[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc (BCAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,618,290
  • Shares Outstanding, K 65,704
  • Annual Sales, $ 0 K
  • Annual Income, $ -137,950 K
  • EBIT $ -174 M
  • EBITDA $ -174 M
  • 60-Month Beta -0.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.03

Options Overview Details

View History
  • Implied Volatility 86.74% (+5.00%)
  • Historical Volatility 61.47%
  • IV Percentile 30%
  • IV Rank 19.11%
  • IV High 321.03% on 09/26/25
  • IV Low 31.38% on 09/08/25
  • Expected Move (DTE 8) 0.94 (3.89%)
  • Put/Call Vol Ratio 21.50
  • Today's Volume 45
  • Volume Avg (30-Day) 171
  • Put/Call OI Ratio 1.67
  • Today's Open Interest 5,225
  • Open Int (30-Day) 3,520
  • Expected Range 23.12 to 24.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.85
  • Number of Estimates 6
  • High Estimate $-0.78
  • Low Estimate $-0.90
  • Prior Year $-0.67
  • Growth Rate Est. (year over year) -26.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.80 +5.66%
on 08/11/26
28.92 -16.70%
on 07/27/26
-4.06 (-14.42%)
since 07/13/26
3-Month
18.62 +29.38%
on 05/19/26
30.99 -22.27%
on 07/07/26
+3.10 (+14.77%)
since 05/13/26
52-Week
10.30 +134.00%
on 09/22/25
30.99 -22.27%
on 07/07/26
+12.76 (+112.62%)
since 08/13/25

Most Recent Stories

More News
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027  Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board...

BCAX : 24.12 (-2.07%)
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 24.12 (-2.07%)
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 24.12 (-2.07%)
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 24.12 (-2.07%)
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the...

BCAX : 24.12 (-2.07%)
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

    At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective...

BCAX : 24.12 (-2.07%)
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy...

BCAX : 24.12 (-2.07%)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 24.12 (-2.07%)
Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while...

BCAX : 24.12 (-2.07%)
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up...

BCAX : 24.12 (-2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead asset includes ficerafusp alfa. Bicara Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 26.48
2nd Resistance Point 25.81
1st Resistance Point 25.22
Last Price 24.12
1st Support Level 23.96
2nd Support Level 23.29
3rd Support Level 22.70

See More

52-Week High 30.99
Last Price 24.12
Fibonacci 61.8% 23.08
Fibonacci 50% 20.64
Fibonacci 38.2% 18.20
52-Week Low 10.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.